Coating Additives – Enhancing Performance, Sustainability, and Innovation
Coating additives are specialized chemical substances used in small quantities to improve the performance and functionality of paints, coatings, and inks. These additives enhance properties such as dispersion, wetting, defoaming, leveling, adhesion, UV resistance, and durability. They play a crucial role in optimizing coating formulations for various surfaces and end-use applications, making them indispensable in industries such as automotive, construction, packaging, and electronics.
In recent years, the coating additives sector has experienced significant growth, driven by increasing demand for high-performance, sustainable, and eco-friendly coating solutions. These additives are widely used in decorative and industrial coatings, printing inks, and adhesives. The surge in construction, automotive refinishing, and digital printing applications has contributed to this upward trajectory. Furthermore, the shift toward waterborne and low-VOC formulations continues to open new avenues for innovation and adoption of advanced additives.
Evonik Coating Additives: Driving Innovation and Sustainability in 2025
New AERODISP Dispersions for Digital Printing
In 2025, Evonik Coating Additives launched four new AERODISP dispersions based on silica (SiO₂) and alumina (Al₂O₃) particles aimed at enhancing waterborne inkjet ink receptive coatings. These dispersions offer excellent dot sharpness and high resolution, critical to the transition from analog to digital printing. By improving ink fixation and spreading behavior on substrates, they elevate the quality of digital prints. This innovation is expected to accelerate the adoption of digital printing technologies, especially in packaging and publishing, boosting demand for performance additives tailored for inkjet formulations.
Introduction of Mass Balanced Additives with Reduced Carbon Footprint
Evonik introduced TEGO Wet 270 eCO and TEGO Foamex 812 eCO, its first mass-balanced wetting agent and defoamer with a significantly reduced carbon footprint. Produced using ISCC-certified raw materials, these sustainable products deliver the same high-performance standards as their conventional counterparts while supporting global sustainability goals. This move positions Evonik as a leader in green chemistry and is likely to influence more coating manufacturers to adopt carbon-conscious formulations, expanding the market for eco-friendly coating additives.
Strategic Partnership with Nippon Paint China
Evonik's collaboration with Nippon Paint China marks a strategic milestone aimed at co-developing next-generation coating solutions. This partnership combines Evonik's advanced additive technologies with Nippon's market leadership in Asia. The joint focus on sustainability and performance is expected to yield innovative products that meet evolving regulatory standards and consumer preferences for environmentally responsible coatings. This alliance will likely set new benchmarks in the Asian coating sector, reinforcing Evonik's footprint and elevating competition through innovation.
Future Outlook
The future of the coating additives industry is poised for robust expansion, fueled by innovation, environmental regulations, and evolving customer demands. With rising investments in R&D and a strong focus on sustainability, the sector is expected to witness the introduction of smarter, multifunctional, and greener additives. Strategic collaborations, like that of Evonik and Nippon Paint, will further shape the global landscape, driving breakthroughs in formulation science and application performance. As digital printing, energy-efficient buildings, and electric vehicles gain traction, the demand for advanced coating additives will continue to surge across regions and industries.
About the Author:
HTF Market Intelligence is a leading market research company providing end-to-end syndicated and custom market reports, consulting services, and insightful information across the globe. With over 15,000+ reports from 27 industries covering 60+ geographies, value research report, opportunities, and cope with the most critical business challenges, and transform businesses. Analysts at HTF MI focus on comprehending the unique needs of each client to deliver insights that are most suited to their particular requirements.
TIME BUSINESS NEWS
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Vietnam scraps 2-child policy as aging threatens economic growth
HANOI, Vietnam (AP) — Vietnam abolished its long-standing two-child limit Tuesday to try and reverse declining birth rates and ease the pressures of an aging population. The National Assembly passed amendments scrapping rules that limit families to having one or two children, state media Vietnam News Agency reported Wednesday. The rules were usually stricter for Communist Party members, who could miss out on promotions or bonuses if they had a third child. Vietnamese families are having fewer children than ever before. The birth rate in 2021 was 2.11 children per woman, just over the replacement rate required for a population to avoid shrinking over the long term. Since then, the birth rate has steadily declined: to 2.01 in 2022, 1.96 in 2023 and 1.91 in 2024. Vietnam isn't the only Asian country with low fertility. But, unlike Japan, South Korea or Singapore, it is still a developing economy. Nguyen Thu Linh, 37, a marketing manager in Vietnam's capital Hanoi, said she and her husband decided to have only one child because they wanted to give their 6-year-old son the best education and upbringing that they could afford. 'Sometimes, I think about having another child so my son can have a sibling, but there's so much financial and time pressure if you have another child,' she said. Vietnam introduced rules blocking families from having more than two children in 1988 to reduce pressure on limited resources after years of war, first with France and then the United States, as the country transitioned into a more market-oriented economy. The population rose from about 62 million then to just over 100 million in 2023, the most recent year for which data is available. Vietnam's 'golden population' period — when working age people outnumber those who depend on them — began in 2007 and is expected to last until 2039. The number of people who can work is likely to peak in 2042 and, by 2054, the population may start shrinking. All of this could make it harder to grow the economy, since there will be fewer workers while the cost of supporting the needs of the elderly increases. Birth rates in Vietnam aren't falling evenly. In Ho Chi Minh City — the country's biggest city and economic hub — the fertility rate in 2024 was just 1.39 children per woman, much lower than the national average. At the same time, nearly 12% of the city's population was over 60, putting pressure on welfare services. To help, local officials started offering about $120 to women who have two children before turning 35 last December. It also offers some of the most generous family benefits in the region, including six months of fully paid maternity leave and free healthcare for children under 6. Tuition in government schools is free until the age of 15 and, starting in September it'll be free till the end of high school. Vietnam is also dealing with a unbalanced gender ratio, partly due to long-standing preferences for sons. According to state media, the distortion is more concentrated in Vietnam's northern Red River delta, which includes Hanoi. Doctors aren't allowed to tell parents the baby's sex before birth, and sex-selective abortions are banned. But despite this, some still hint at the baby's sex using coded language, said state media VN Express, citing a government report. On Tuesday, the health ministry proposed tripling the fine for choosing a baby's sex before birth to $3,800, state media reported. China imposed a one-child policy in 1979 amid worries about overpopulation. But as the country faces growing concerns about the long-term economic and societal challenges of an aging population, it has been slowly easing the policy to allow a second child and then a third child in 2021, but with little success in boosting birthrates. ___ Associated Press journalist Hau Dinh contributed to this report. Aniruddha Ghosal, The Associated Press
Yahoo
an hour ago
- Yahoo
HighTide Therapeutics And 2 Other Asian Penny Stocks To Watch Closely
Amidst a backdrop of fluctuating global trade policies and easing inflation, Asian markets have been navigating a complex economic landscape. For investors eyeing opportunities in smaller or newer companies, penny stocks—though an outdated term—still hold potential for growth at accessible price points. These stocks can offer notable value when backed by strong financials, making them intriguing options for those seeking hidden gems with promising long-term prospects. Name Share Price Market Cap Financial Health Rating Halcyon Technology (SET:HTECH) THB2.64 THB792M ★★★★★★ CNMC Goldmine Holdings (Catalist:5TP) SGD0.445 SGD180.35M ★★★★★☆ Beng Kuang Marine (SGX:BEZ) SGD0.176 SGD35.06M ★★★★★★ Yangzijiang Shipbuilding (Holdings) (SGX:BS6) SGD2.21 SGD8.7B ★★★★★☆ BRC Asia (SGX:BEC) SGD3.13 SGD858.72M ★★★★★★ Ever Sunshine Services Group (SEHK:1995) HK$1.90 HK$3.28B ★★★★★☆ Bosideng International Holdings (SEHK:3998) HK$4.39 HK$50.26B ★★★★★★ Lever Style (SEHK:1346) HK$1.15 HK$725.59M ★★★★★★ Goodbaby International Holdings (SEHK:1086) HK$1.20 HK$2B ★★★★★★ TK Group (Holdings) (SEHK:2283) HK$2.04 HK$1.7B ★★★★★★ Click here to see the full list of 1,161 stocks from our Asian Penny Stocks screener. Here we highlight a subset of our preferred stocks from the screener. Simply Wall St Financial Health Rating: ★★★★★☆ Overview: HighTide Therapeutics, Inc. is a biopharmaceutical company focused on discovering, researching, developing, and commercializing therapies for metabolic and digestive diseases in Mainland China, with a market cap of HK$1.42 billion. Operations: HighTide Therapeutics, Inc. has not reported any specific revenue segments at this time. Market Cap: HK$1.42B HighTide Therapeutics, Inc., a pre-revenue biopharmaceutical company, recently announced positive Phase 3 trial results for its lead compound HTD1801 in treating type 2 diabetes mellitus. Despite its lack of revenue and current unprofitability, the company has a strong financial position with short-term assets exceeding liabilities and more cash than debt. The management team is experienced, although the board is relatively new. HighTide's stock remains highly volatile, reflecting typical penny stock characteristics. The upcoming NDA submission for HTD1801 could be pivotal if approved by China's regulatory authorities later this year. Take a closer look at HighTide Therapeutics' potential here in our financial health report. Gain insights into HighTide Therapeutics' past trends and performance with our report on the company's historical track record. Simply Wall St Financial Health Rating: ★★★★☆☆ Overview: Shandong Molong Petroleum Machinery Company Limited, along with its subsidiaries, focuses on the design, research and development, production, and sale of energy equipment products and services both in China and internationally, with a market cap of HK$3.06 billion. Operations: No specific revenue segments are reported for Shandong Molong Petroleum Machinery Company Limited. Market Cap: HK$3.06B Shandong Molong Petroleum Machinery has shown a mix of financial challenges and operational resilience. Despite being unprofitable, the company maintains a positive cash runway for over three years, supported by CN¥2 billion in short-term assets exceeding its liabilities. However, its high net debt to equity ratio of 201.3% and increased debt levels highlight financial strain. The recent earnings report shows improved revenue but a significant drop in net income compared to the previous year, indicating volatility typical of penny stocks. Management's lack of experience could impact strategic decisions as they navigate these complexities. Unlock comprehensive insights into our analysis of Shandong Molong Petroleum Machinery stock in this financial health report. Assess Shandong Molong Petroleum Machinery's previous results with our detailed historical performance reports. Simply Wall St Financial Health Rating: ★★★★★★ Overview: Chongqing Lummy Pharmaceutical Co., Ltd. is involved in the research and development, manufacture, and sale of pharmaceutical products in China with a market cap of CN¥3.92 billion. Operations: The company's revenue is primarily generated from its operations in China, amounting to CN¥812.87 million. Market Cap: CN¥3.92B Chongqing Lummy Pharmaceutical faces financial challenges typical of penny stocks, with a net loss of CN¥13.78 million reported for Q1 2025 despite revenue growth to CN¥198.4 million. The company is unprofitable but has improved its debt profile, reducing the debt-to-equity ratio from 74.9% to 18.6% over five years and maintaining more cash than total debt, providing a stable cash runway exceeding three years even if free cash flow declines. Short-term assets of CN¥1.5 billion comfortably cover liabilities, though ongoing losses necessitate careful management by its experienced leadership team averaging over eight years in tenure. Click to explore a detailed breakdown of our findings in Chongqing Lummy Pharmaceutical's financial health report. Review our historical performance report to gain insights into Chongqing Lummy Pharmaceutical's track record. Click this link to deep-dive into the 1,161 companies within our Asian Penny Stocks screener. Looking For Alternative Opportunities? The end of cancer? These 23 emerging AI stocks are developing tech that will allow early idenification of life changing disesaes like cancer and Alzheimer's. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include SEHK:2511 SEHK:568 and SZSE:300006. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
Yahoo
2 hours ago
- Yahoo
Asian Dividend Stocks To Watch In June 2025
As Asian markets navigate a landscape marked by trade negotiations and economic policy shifts, investors are keenly observing the region's dividend stocks for potential opportunities. In this environment, a good dividend stock is often characterized by its ability to maintain stable payouts despite market volatility, making them an attractive option for income-focused investors looking to weather economic uncertainties. Name Dividend Yield Dividend Rating Yamato Kogyo (TSE:5444) 4.39% ★★★★★★ Wuliangye YibinLtd (SZSE:000858) 5.09% ★★★★★★ Japan Excellent (TSE:8987) 4.39% ★★★★★★ GakkyushaLtd (TSE:9769) 4.04% ★★★★★★ en-japan (TSE:4849) 4.28% ★★★★★★ E J Holdings (TSE:2153) 5.32% ★★★★★★ Daito Trust ConstructionLtd (TSE:1878) 4.41% ★★★★★★ Daicel (TSE:4202) 4.92% ★★★★★★ CAC Holdings (TSE:4725) 4.89% ★★★★★★ Asian Terminals (PSE:ATI) 6.38% ★★★★★★ Click here to see the full list of 1231 stocks from our Top Asian Dividend Stocks screener. Let's explore several standout options from the results in the screener. Simply Wall St Dividend Rating: ★★★★★☆ Overview: Woori Financial Group Inc. operates as a commercial bank offering a variety of financial services to individual, business, and institutional clients in Korea, with a market cap of approximately ₩14.90 trillion. Operations: Woori Financial Group Inc.'s revenue segments include Banking at ₩7.81 billion, Capital at ₩291.32 million, Credit Cards at ₩520.77 million, and Investment Securities at ₩66.84 million. Dividend Yield: 5.9% Woori Financial Group's dividend yield ranks in the top 25% of Korean market payers, supported by a low payout ratio of 33.2%, indicating dividends are well-covered by earnings. However, its dividend track record is volatile over the past decade, with recent decreases. The company trades at a significant discount to its estimated fair value and has completed a share buyback worth KRW 25.64 billion, reflecting efforts to enhance shareholder value amid fluctuating earnings performance. Dive into the specifics of Woori Financial Group here with our thorough dividend report. Our valuation report here indicates Woori Financial Group may be undervalued. Simply Wall St Dividend Rating: ★★★★★☆ Overview: Cosco Capital, Inc. operates in the Philippines through its subsidiaries across various sectors including retail, real estate, liquor distribution, oil and mineral exploration, and specialty retail businesses with a market cap of ₱48.75 billion. Operations: Cosco Capital, Inc.'s revenue is primarily derived from its grocery retail segment at ₱224.27 billion, followed by liquor distribution at ₱19.23 billion, real estate and property leasing at ₱2.04 billion, specialty retail at ₱2.09 billion, and energy and minerals exploration contributing ₱534.44 million in the Philippines. Dividend Yield: 7.6% Cosco Capital's dividend yield is among the top 25% in the Philippine market, with a low cash payout ratio of 20.7%, ensuring dividends are well-supported by cash flows. Despite this financial strength, its dividend history over the past decade has been volatile and unreliable. The company trades at a favorable valuation compared to peers and has demonstrated recent earnings growth. A special cash dividend of PHP 0.132 per share was announced for September 2025, alongside regular dividends totaling PHP 1.86 billion for June payment. Unlock comprehensive insights into our analysis of Cosco Capital stock in this dividend report. According our valuation report, there's an indication that Cosco Capital's share price might be on the cheaper side. Simply Wall St Dividend Rating: ★★★★☆☆ Overview: Jinan Acetate Chemical Co., Ltd. operates in the research, development, production, and sale of cellulose acetate products across multiple continents and has a market cap of NT$92.88 billion. Operations: Jinan Acetate Chemical Co., Ltd. generates revenue primarily from the research and development and manufacturing of fiber acetate products, amounting to NT$16.25 billion. Dividend Yield: 5.3% Jinan Acetate Chemical offers a dividend yield in the top 25% of Taiwan's market, with dividends covered by earnings (56.9% payout ratio) and cash flows (80.1% cash payout ratio). However, its dividend history is unstable, having been paid for less than a decade with volatility. The company's shares trade significantly below estimated fair value and recent earnings report shows growth in sales to TWD 4.15 billion for Q1 2025, though net income slightly declined year-over-year. Click to explore a detailed breakdown of our findings in Jinan Acetate Chemical's dividend report. Our expertly prepared valuation report Jinan Acetate Chemical implies its share price may be lower than expected. Discover the full array of 1231 Top Asian Dividend Stocks right here. Have you diversified into these companies? Leverage the power of Simply Wall St's portfolio to keep a close eye on market movements affecting your investments. Invest smarter with the free Simply Wall St app providing detailed insights into every stock market around the globe. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include KOSE:A316140 PSE:COSCO and TWSE:4763. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
